Pharmaceutical Market Europe • October 2025 • 36
APPOINTMENTS
Sanofi
Lisa Sha
Sanofi has appointed Lisa Sha as General Manager, vaccines, for the UK and Ireland. She takes up the role with immediate effect and will be based at the company’s UK headquarters. The appointment will support Sanofi’s advancement in vaccinations in the UK and Ireland.
Sha joined Sanofi in 2019 and has held senior leadership positions spanning cardiovascular therapies, transplantation and general medicines. Prior to working at Sanofi, she worked in marketing, strategy and transformation roles in both the US and Europe. Notably, she was senior product manager at Philips and a consultant at ClearView Pharmaceuticals.
Karine Labaky, head of key markets, vaccines at Sanofi said: “Lisa’s strategic mindset and dynamic leadership approach will be invaluable.”
Merck
David Weinreich
Merck (known as MSD outside the US and Canada) has appointed David Weinreich as its Global Head of R&D and Chief Medical Officer of its Healthcare business sector. Weinreich previously served as an Operating Partner and Senior Advisor at Foresite Labs & Foresite Capital Management, and has held senior leadership roles at Regeneron, Bayer and Amgen.
Johnson & Johnson
John Morikis
Johnson & Johnson has welcomed John Morikis to its board of directors. He also currently serves on the boards of United Parcel Service, General Mills and Whirlpool Corporation, as well as Chairman of the board for University Hospitals Health System. Morikis is the retired Executive Chairman, President, and Chief Executive Officer of the Sherwin-Williams Company.
CNX Therapeutics
Emma Bush
CNX Therapeutics has appointed Emma Bush as Vice President, Commercial. Bush joins CNX Therapeutics from Galderma SA, where she served as Head of Global Accounts and Business Services. She brings extensive global experience to the company, having account management experience at both GSK and Teva, driving growth across pharma and consumer health portfolios.
Orbital Therapeutics
Adam Raff
Orbital Therapeutics has appointed Adam Raff as Senior Vice President, Clinical Development, overseeing its clinical and regulatory strategy. His experience includes early and late-stage drug development and clinical research, particularly in immunology and inflammatory conditions. He has held leadership roles at Montai Therapeutics, EQRx (acquired by Revolution Medicines) and LeoPharma.
Eli Lilly
Peter Marks
Eli Lilly has appointed Peter Marks as Senior Vice President of Molecule Discovery and Head of Infectious Diseases. Marks previously served as the director of the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) and was the agency’s chief vaccine regulator before his resignation in March.
hVIVO
Shaun Chilton
hVIVO has appointed Shaun Chilton to its Board of Directors as Non-Executive Chair. Chilton brings over 30 years of experience of senior leadership to the role, previously serving as CEO of Clinigen. He currently also serves as Non-Executive Chair of Avacta Group, Non-Executive Chair of Kintiga, and Independent Supervisory Board Member of Product Life Group.
FairJourney Biologics
Werner Lanthaler
FairJourney Biologics has appointed Dr Werner Lanthaler as CEO. He brings decades of experience to the role – he previously served as CEO of Evotec for 15 years, leading its global expansion and drug discovery and precision medicine capabilities. Prior to Evotec, he was Chief Financial Officer at Intercell, driving its initial public offering.
Yellowstone Biosciences
James MacDonald
Yellowstone Biosciences has appointed James MacDonald as Chief Executive Officer and member of the board of directors. He brings over 25 years of experience to Yellowstone, serving as a Venture Partner at Altitude Life Sciences Ventures prior to joining Yellowstone. He also co-founded Sana Biotechnology, serving as Executive Vice President and General Counsel.
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services